Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 35

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 35
---
 sales force, TELI may be unable to effectively train and equip TELI’s sales force, therefore TELI’s ability to successfully commercialize TELI’s products may be harmed.

We may be required to expend significant time and resources to train TELI’s sales force to be credible, persuasive and compliant with applicable laws in marketing TELI’s product candidates to physicians for their approval. In addition, TELI must continue to train its sales force to ensure that a consistent and appropriate message about TELI’s product candidates delivered to TELI’s potential customers. If TELO is unable to effectively train its sales force and equip them with effective materials, including medical and sales literature, to help them inform and educate potential customers about the benefits of Telomir-1 and TELI’s product candidates and its proper administration, TELI’s efforts to successfully commercialize its product candidates could be jeopardized, which would negatively impact TELI’s ability to generate product revenues.

The manufacture of TELI’s product candidates is complex and uncertain, and until TELI develops a validated manufacturing process, TELI may encounter difficulties in supplying its planned and future clinical trials. If TELI encounters such difficulties, or fails to meet quality standards, TELI’s ability to meet clinical timelines and expand its development strategy could be impacted.

The processes involved in manufacturing TELI’s product candidate is complex, expensive, highly regulated and subject to multiple risks and uncertainties. In addition, as product candidates are developed through early to late-stage clinical trials and then to approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are modified along the way to optimize the scale, process and results. Any changes to the manufacturing processes carry the risk that they will not achieve these intended objectives, or that the product candidates may not meet the rigorous quality standards necessary for use in TELI’s pre-clinical or clinical trials.

Also, if planned or future manufacturing of TELI’s product candidates fails to meet the quality standards for use in its pre-clinical or clinical trials, or the active drug substance does not meet its quality specifications, it could impact TELI’s timelines and limit its development strategy.

TELI’s management and personnel, systems, and facilities currently in place may not be adequate to support its business plan and future growth. As a result, TELI may need to further expand certain areas of its organization.

TELI’s operations, growth and various